Climb Bio (CLYM) Institutional Ownership $2.45 +0.22 (+9.87%) As of 03:09 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Climb Bio (NASDAQ:CLYM)CurrentInstitutional OwnershipPercentage69.76%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$43.59MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$568.41K Get CLYM Insider Trade Alerts Want to know when executives and insiders are buying or selling Climb Bio stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CLYM Institutional Buying and Selling by Quarter Climb Bio Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Shay Capital LLC415,000$515K0.1%+107.5%0.612% 8/14/2025 Jane Street Group LLC148,180$184K0.0%N/A0.219% 8/14/2025 Diadema Partners LP702,135$871K0.3%+4.8%1.039% 8/14/2025 Qube Research & Technologies Ltd34,310$43K0.0%N/A0.051% 8/13/2025 Marshall Wace LLP36,738$46K0.0%N/A0.054% 8/13/2025 Stonepine Capital Management LLC116,147$144K0.1%N/A0.172% 8/12/2025 JPMorgan Chase & Co.210,122$261K0.0%-31.4%0.311% 8/8/2025 Geode Capital Management LLC311,721$387K0.0%-53.7%0.461% 8/8/2025 Nan Fung Trinity HK Ltd.463,654$575K0.1%N/A0.686% 8/1/2025 Y Intercept Hong Kong Ltd127,952$159K0.0%N/A0.189% 6/27/2025 Goldman Sachs Group Inc.120,742$147K0.0%N/A0.179% 5/16/2025 Goldman Sachs Group Inc.120,742$147K0.0%N/A0.179% 5/16/2025 AQR Capital Management LLC21,808$27K0.0%N/A0.032% 5/16/2025 Allostery Investments LP244,988$299K0.4%N/A0.363% 5/16/2025 ADAR1 Capital Management LLC119,320$146K0.0%N/A0.177% 5/15/2025 RA Capital Management L.P.31,419,267$38.33M0.6%N/A46.495% 5/14/2025 Affinity Asset Advisors LLC1,500,000$1.83M0.2%N/A2.220% 5/13/2025 Persistent Asset Partners Ltd145,760$178K0.1%N/A0.216% 5/12/2025 Nuveen LLC39,034$48K0.0%N/A0.058% 5/9/2025 Charles Schwab Investment Management Inc.70,093$86K0.0%N/A0.104% 5/8/2025 XTX Topco Ltd27,660$34K0.0%N/A0.041% 5/7/2025 TD Asset Management Inc89,400$109K0.0%N/A0.132% 4/30/2025 Peapod Lane Capital LLC553,816$676K0.8%N/A0.821% 4/29/2025 Bank of New York Mellon Corp64,914$79K0.0%N/A0.096% (Data available from 1/1/2016 forward) CLYM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CLYM shares? During the previous two years, 23 institutional investors and hedge funds held shares of Climb Bio. The most heavily invested institutionals were RA Capital Management L.P. ($38.33M), Affinity Asset Advisors LLC ($1.83M), Diadema Partners LP ($871K), Peapod Lane Capital LLC ($676K), Nan Fung Trinity HK Ltd. ($575K), Shay Capital LLC ($515K), and Geode Capital Management LLC ($387K).Learn more on Climb Bio's institutional investors. What percentage of Climb Bio's stock is owned by institutional investors? 69.76% of Climb Bio's stock is owned by institutional investors. Learn more on CLYM's institutional investor holdings. Which institutional investors have been buying Climb Bio's stock? Of the 21 institutional investors that purchased Climb Bio's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($31.42M), Affinity Asset Advisors LLC ($1.50M), Peapod Lane Capital LLC ($553.82K), Nan Fung Trinity HK Ltd. ($463.65K), Allostery Investments LP ($244.99K), Goldman Sachs Group Inc. ($241.48K), and Shay Capital LLC ($215K). How much institutional buying is happening at Climb Bio? Institutional investors have bought a total of 35,711,857 shares in the last 24 months. This purchase volume represents approximately $43.59M in transactions. Which of Climb Bio's major shareholders have been selling company stock? The following institutional investors have sold Climb Bio stock in the last 24 months: Geode Capital Management LLC ($362.09K), and JPMorgan Chase & Co. ($96.30K). How much institutional selling is happening at Climb Bio? Institutional investors have sold a total of 458,392 shares in the last 24 months. This volume of shares sold represents approximately $568.41K in transactions. Related Companies Relay Therapeutics Institutional Ownership Organogenesis Institutional Ownership Tourmaline Bio Institutional Ownership Terns Pharmaceuticals Institutional Ownership MeiraGTx Institutional Ownership Maravai LifeSciences Institutional Ownership Arvinas Institutional Ownership Siga Technologies Institutional Ownership Xencor Institutional Ownership AnaptysBio Institutional Ownership This page (NASDAQ:CLYM) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
